Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase NA 1Phase 4 1Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Recurrence 1Patients With Nonmyeloid Malignancies Receiving Antineoplastic Therapy Based on Chemotherapy Regimens at Moderate to High Febrile Neutropenia (FN) Risk 1Neutropenia 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Hodgkin Disease 1Febrile Neutropenia 1Esophageal Neoplasms 1Breast Neoplasms 1

Interventions

pegfilgrastim 13Filgrastim 8Cyclophosphamide 3liposomal amphotericin B 2eflapegrastim 2Peripheral Blood Stem Cell Transplantation 2Mitoxantrone 2Levofloxacin 2Idarubicin 2Fluconazole 2Etoposide 2Docetaxel 2Cytarabine 2Ciprofloxacin 2Cefepime 2Caspofungin 2Amsacrine 2pegylated granulocyte colony-stimulating factor 1ceftobiprole medocaril 1Vancomycin 1Tretinoin 1Thioguanine 1Radiotherapy 1Psychiatric Rehabilitation 1MYL-1401H 1Lithium Carbonate 1Granulocyte-Macrophage Colony-Stimulating Factor 1Granulocyte Colony-Stimulating Factor 1Daunorubicin 1Carmustine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Neutropenia × pegylated granulocyte colony-stimulating factor × Clear all
NCT04466137 2022-02-09

Phase 3 Study to Evaluate the Safety and Efficacy of YPEG-rhG-CSF in Malignancies Receiving Chemotherapy

Xiamen Amoytop Biotech Co., Ltd.

Phase 3 Completed
398 enrolled
Classical hematology

Neutropenia, Febrile Neutropenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡